Literature DB >> 20448066

Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.

Naji Younes1, Patricia A Cleary, Michael W Steffes, Ian H de Boer, Mark E Molitch, Brandy N Rutledge, John M Lachin, William Dahms.   

Abstract

BACKGROUND AND OBJECTIVES: The objective of this study was to compare random urine albumin-creatinine ratio (ACR) with timed urine albumin excretion rate (AER) in patients with type 1 diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 1186 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study provided spot urine specimens concurrent with 4-hour timed urine collections. ACR and AER were compared using Bland-Altman plots, cross-classification of albuminuria status and its change over time, and within-person variability.
RESULTS: Despite moderate correlation (r=0.62), ACR levels (mg/g) were lower than AER levels (mg/24 hr). This difference was greatest for men. Gender-specific estimated AER (eAER) values were empirically derived from ACR. Comparing the eAER with measured AER, agreement of prevalent microalbuminuria and macroalbuminuria classification was fair to moderate, and classification of change in albuminuria status over time was different. Intraclass correlations were 0.697 for ACR and 0.803 for AER. Effects of DCCT intensive versus conventional diabetes therapy on urine albumin excretion or classification of albuminuria were similar using the eAER versus measured AER, as were the effects of the previous glycosylated hemoglobin.
CONCLUSIONS: Systematic differences exist between urine ACR and AER, related to gender and other determinants of muscle mass. Use of ACR (or eAER) versus AER yields differences in classification of prevalent albuminuria states and changes in albuminuria states over time. These findings support the use of consistent ascertainment methods over time and further efforts to standardize and optimally interpret measurement of urine albumin excretion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448066      PMCID: PMC2893069          DOI: 10.2215/CJN.07901109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  22 in total

1.  First morning voids are more reliable than spot urine samples to assess microalbuminuria.

Authors:  Elsbeth C Witte; Hiddo J Lambers Heerspink; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ronald Gansevoort
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

2.  Random urine albumin:creatinine ratio measurements as a screening test for diabetic microalbuminuria--a five year follow up.

Authors:  P J Dunn; D R Jury
Journal:  N Z Med J       Date:  1990-11-28

3.  Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.

Authors: 
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Single-void urine samples can be used to estimate quantitative microalbuminuria.

Authors:  D M Nathan; C Rosenbaum; V D Protasowicki
Journal:  Diabetes Care       Date:  1987 Jul-Aug       Impact factor: 19.112

6.  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.

Authors: 
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens.

Authors:  R G Nelson; W C Knowler; D J Pettitt; M F Saad; M A Charles; P H Bennett
Journal:  Arch Intern Med       Date:  1991-09

9.  Influence of biological variations and sample handling on measured microalbuminuria in diabetic patients.

Authors:  I Vermes; P F Spooren
Journal:  J Clin Lab Anal       Date:  1992       Impact factor: 2.352

10.  Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio.

Authors:  J H Warram; G Gearin; L Laffel; A S Krolewski
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

View more
  26 in total

1.  Risk Factors for Kidney Disease in Type 1 Diabetes.

Authors:  Bruce A Perkins; Ionut Bebu; Ian H de Boer; Mark Molitch; William Tamborlane; Gayle Lorenzi; William Herman; Neil H White; Rodica Pop-Busui; Andrew D Paterson; Trevor Orchard; Catherine Cowie; John M Lachin
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

2.  Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study.

Authors:  Dean P Hainsworth; Ionut Bebu; Lloyd P Aiello; William Sivitz; Rose Gubitosi-Klug; John Malone; Neil H White; Ronald Danis; Amisha Wallia; Xiaoyu Gao; Andrew J Barkmeier; Arup Das; Shriji Patel; Thomas W Gardner; John M Lachin
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

3.  Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.

Authors:  Rose A Gubitosi-Klug; Barbara H Braffett; Susan Hitt; Valerie Arends; Diane Uschner; Kimberly Jones; Lisa Diminick; Amy B Karger; Andrew D Paterson; Delnaz Roshandel; Santica Marcovina; John M Lachin; Michael Steffes; Jerry P Palmer
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

4.  Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.

Authors:  Ian H de Boer; Xiaoyu Gao; Patricia A Cleary; Ionut Bebu; John M Lachin; Mark E Molitch; Trevor Orchard; Andrew D Paterson; Bruce A Perkins; Michael W Steffes; Bernard Zinman
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 8.237

Review 5.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

6.  Measures of Kidney Disease and the Risk of Venous Thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.

Authors:  Katharine L Cheung; Neil A Zakai; Aaron R Folsom; Manjula Kurella Tamura; Carmen A Peralta; Suzanne E Judd; Peter W Callas; Mary Cushman
Journal:  Am J Kidney Dis       Date:  2017-01-23       Impact factor: 8.860

7.  Urine podocyte mRNAs mark disease activity in IgA nephropathy.

Authors:  Akihiro Fukuda; Yuji Sato; Takashi Iwakiri; Hiroyuki Komatsu; Masao Kikuchi; Kazuo Kitamura; Roger C Wiggins; Shouichi Fujimoto
Journal:  Nephrol Dial Transplant       Date:  2015-05-08       Impact factor: 5.992

8.  Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.

Authors:  Dean P Hainsworth; Xiaoyu Gao; Ionut Bebu; Arup Das; Lisa Olmos de Koo; Andrew J Barkmeier; William Tamborlane; John M Lachin; Lloyd Paul Aiello
Journal:  Ophthalmology       Date:  2020-09-14       Impact factor: 12.079

9.  Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study.

Authors:  Ionut Bebu; Barbara H Braffett; Trevor J Orchard; Gayle M Lorenzi; David M Nathan; William H Herman; John M Lachin
Journal:  Diabetes Res Clin Pract       Date:  2020-12-10       Impact factor: 5.602

10.  Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Authors:  Barbara H Braffett; Rose A Gubitosi-Klug; James W Albers; Eva L Feldman; Catherine L Martin; Neil H White; Trevor J Orchard; Maria Lopes-Virella; John M Lachin; Rodica Pop-Busui
Journal:  Diabetes       Date:  2020-02-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.